Document is current

Article History

Received: 27 March 2020

Accepted: 27 April 2021

First Online: 18 May 2021

Declarations

:

: Tumor samples of four patients with high-grade serous ovarian cancer (OC) and six patients with metastatic castration-resistant prostate cancer (PC) were used in this study. Patients with OC participated in the 14-472 HUB-OVI study approved by the medical ethical committee UMC Utrecht (METC UMCU), in which tumor tissue and blood were obtained for organoid culture (tumor) and whole genome sequencing (WGS) (tumor and blood). Clinical data was extracted from the patient file in collaboration with the Dutch Cancer Registration. Patients with PC participated in both the CPCT-02 study (NCT01855477) and the CIRCUS study (NTR5732), in which tumor tissue from a metastatic lesion for WGS and longitudinal cfDNA samples were obtained. Longitudinal ctDNA quantification was performed for four patients with PC. Written informed consent to participate was obtained for all studies. Clinical data for patients with PC were collected in an electronic case report form (ALEA Clinical). All studies were performed according to the guidelines of the European Network of Research Ethics Committees (EUREC) following European, national, and local law. The research performed here conformed to the principles of the Helsinki Declaration.

: Not applicable.

: J.E.V-I, C.S., and W.P.K. have received financial compensation for travel and accommodation expenses to speak at Oxford Nanopore Technologies-organized meetings. W.P.K. is co-founder and shareholder of Cyclomics. The remaining authors declare no competing interests.